PTGX Protagonist Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: PTGX
- PE Ratio
As at May 23, 2025, the PTGX stock has a PE ratio of 50.73. This is based on the current EPS of $0.9 and the stock price of $45.66 per share. An increase of 125% has been seen in the P/E ratio compared to the average of 22.5 of the last 4 quarters.
PTGX PE ratio history
The mean historical PE ratio of Protagonist Therapeutics over the last eight years is 24.92. The current 50.73 PE ratio is 104% above the historical average. Over the past eight years, PTGX's PE ratio was at its highest in the Mar 2025 quarter at 53.73, with a price of $48.36 and an EPS of $0.9. The Dec 2024 quarter recorded the bottom point at 8.64, with a price of $38.6 and an EPS of $4.47.
Protagonist Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 8.64 | N/A | $38.6 | $4.47 |
| 2023 | N/A | N/A | $22.93 | -$1.39 |
| 2022 | N/A | N/A | $10.91 | -$2.6 |
| 2021 | N/A | N/A | $34.2 | -$2.71 |
| 2020 | N/A | N/A | $20.16 | -$1.92 |
| 2019 | N/A | N/A | $7.05 | -$2.98 |
| 2018 | N/A | N/A | $6.73 | -$1.74 |
| 2017 | N/A | N/A | $20.8 | -$2.09 |
| 2016 | N/A | N/A | $21.99 | -$5.8 |
| 2015 | N/A | N/A | N/A | -$59.32 |
| 2014 | N/A | N/A | N/A | -$49.38 |
Protagonist Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 53.73 | 521.88% | $48.36 | $0.9 |
| Dec 2024 | 8.64 | -44.51% | $38.6 | $4.47 |
| Sep 2024 | 15.57 | 28.04% | $45 | $2.89 |
| Jun 2024 | 12.16 | 12.18% | $34.65 | $2.85 |
| Mar 2024 | 10.84 | N/A | $28.93 | $2.67 |
| Dec 2023 | N/A | N/A | $22.93 | -$1.39 |
| Sep 2023 | N/A | N/A | $16.68 | -$2.63 |
| Jun 2023 | N/A | N/A | $27.62 | -$2.69 |
| Mar 2023 | N/A | N/A | $23 | -$2.85 |
| Dec 2022 | N/A | N/A | $10.91 | -$2.6 |
| Sep 2022 | N/A | N/A | $8.43 | -$2.68 |
| Jun 2022 | N/A | N/A | $7.91 | -$2.74 |
| Mar 2022 | N/A | N/A | $23.68 | -$2.59 |
| Dec 2021 | N/A | N/A | $34.2 | -$2.71 |
| Sep 2021 | N/A | N/A | $17.72 | -$2.4 |
PTGX Price vs fair value
PTGX average PE ratio chart
PTGX's current P/E ratio is above the 3 and 5-year historical averages.
PTGX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| PTGX Protagonist Therapeutics Inc | 51.17 | $2.85B |
| OLMA Olema Pharmaceuticals Inc | N/A | $354.42M |
| OMER Omeros Corp | N/A | $185.74M |
| VIVS VivoSim Labs Inc. | N/A | $2.88M |
| ORIC Oric Pharmaceuticals Inc | N/A | $413.73M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $87.83M |
Frequently asked questions
What is Protagonist Therapeutics's PE ratio?
The price to earnings ratio for PTGX stock is 50.73 as of May 23, 2025.
What is the 3-year average PE ratio for Protagonist Therapeutics (PTGX)?
The 3-year average PE ratio for PTGX stock is 20.19.
What is the 5-year average PE ratio for Protagonist Therapeutics (PTGX)?
The 5-year average PE ratio for PTGX stock is 20.19.
What is the highest PE ratio for PTGX?
The highest quarterly PE ratio in the last eight years has been 53.73 and it was in the Mar 2025 quarter.
How does the current PE ratio for PTGX compare to its historical average?
PTGX's current price to earnings ratio is 104% above its 8-year historical average.
How is PTGX's PE ratio calculated (Protagonist Therapeutics PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (May 23, 2025), Protagonist Therapeutics's stock price is $45.66. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $0.9. Therefore, Protagonist Therapeutics's P/E ratio for today is 50.73. PE RATIO(50.73) = STOCK PRICE($45.66) / TTM EPS($0.9)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.